ABVC BioPharma, Inc. (ABVC) — Financial statements
Income statement, balance sheet, and cash flow for ABVC BioPharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.80↑56.2% | 0.51↑234.3% | 0.15↓84.3% | 0.97↑172.6% | 0.36 | |
| Cost of Revenue | 0.50↑66064.4% | 0.00↓99.7% | 0.30↑5.5% | 0.29↑5531.4% | 0.01 | |
| Gross Profit | 0.80↑56.4% | 0.51↑440.1% | -0.15↓121.9% | 0.68↑94.9% | 0.35 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.13↓30.1% | 0.18↓83.1% | 1↓60.5% | 3↑168.3% | 1 | |
| General & Administrative Expenses | 7↑39.6% | 5↓9.4% | 6↓57.6% | 13↑18.6% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 7↑29.6% | 5↓9.4% | 6↓57.6% | 13↑18.6% | 11 | |
| Other Expenses | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 7↑27.5% | 5↓21.2% | 7↓58.1% | 16↑31.0% | 12 | |
| Total Costs & Expenses | 7↑37.1% | 5↓24.6% | 7↓57.0% | 16↑33.3% | 12 | |
| Operating Results | ||||||
| Operating Income | -7↓52.0% | -5↑30.5% | -7↑55.2% | -15↓29.1% | -12 | |
| Depreciation & Amortization | 0.50↑151.3% | 0.20↓47.2% | 0.38↑1498.3% | 0.02↑98.4% | 0.01 | |
| EBITDA | -7↓53.0% | -4↑31.4% | -6↑58.3% | -15↓38.5% | -11 | |
| EBIT | -7↓57.4% | -5↑32.3% | -7↑55.9% | -15↓38.6% | -11 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.25↑66.3% | -0.74↑34.5% | -1↓962.8% | -0.11↑42.3% | -0.18 | |
| Interest Income | 0.17↑91.3% | 0.09↓52.9% | 0.19↓1.2% | 0.19↑334.8% | 0.04 | |
| Interest Expense | 0.42↓49.6% | 0.83↓37.1% | 1↑346.9% | 0.29↑29.4% | 0.23 | |
| Non-Operating Income | 0.00↑100.0% | -0.16↓190.8% | -0.06↓152.3% | 0.11↑114.7% | -0.72 | |
| Other Income / Expenses | -1↓80.9% | -0.66↑47.2% | -1↓214.4% | -0.40↓180.8% | 0.50 | |
| Income Before Tax | -8↓55.6% | -5↑33.1% | -8↑48.3% | -16↓38.4% | -11 | |
| Income Tax Expense | 0.02↑121.9% | -0.11↓143.2% | 0.26↓67.9% | 0.80↓3.3% | 0.83 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -8↓59.3% | -5↑36.5% | -8↑49.2% | -16↓35.5% | -12 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -8↓61.3% | -5↑37.0% | -8↑52.6% | -16↓27.9% | -13 | |
| Bottom-Line Net Income | -8↓61.3% | -5↑37.0% | -8↑52.6% | -16↓27.9% | -13 | |
| EPS (Basic) | -0.39↑7.1% | -0.42↑76.7% | -1.80↑65.4% | -5.20↓2.0% | -5.10 | |
| EPS (Diluted) | -0.39↑7.1% | -0.42↑76.7% | -1.80↑65.4% | -5.20↓2.0% | -5.10 | |
| Weighted Average Shares | 23↑99.2% | 12↑169.3% | 4↑36.9% | 3↑26.4% | 3 | |
| Weighted Average Diluted Shares | 23↑99.2% | 12↑169.3% | 4↑36.9% | 3↑26.4% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.